Spyre Therapeutics (SYRE) Leases: 2019-2023
Historic Leases for Spyre Therapeutics (SYRE) over the last 4 years, with Jun 2023 value amounting to $2.3 million.
- Spyre Therapeutics' Leases fell 35.93% to $2.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.3 million, marking a year-over-year decrease of 35.93%. This contributed to the annual value of $3.4 million for FY2022, which is 9.88% down from last year.
- According to the latest figures from Q2 2023, Spyre Therapeutics' Leases is $2.3 million, which was down 29.09% from $3.3 million recorded in Q1 2023.
- In the past 5 years, Spyre Therapeutics' Leases ranged from a high of $5.0 million in Q2 2019 and a low of $621,000 during Q1 2019.
- For the 3-year period, Spyre Therapeutics' Leases averaged around $3.6 million, with its median value being $3.7 million (2022).
- As far as peak fluctuations go, Spyre Therapeutics' Leases spiked by 658.78% in 2020, and later plummeted by 35.93% in 2023.
- Spyre Therapeutics' Leases (Quarterly) stood at $4.7 million in 2019, then dropped by 10.50% to $4.2 million in 2020, then dropped by 10.02% to $3.8 million in 2021, then dropped by 9.88% to $3.4 million in 2022, then tumbled by 35.93% to $2.3 million in 2023.
- Its last three reported values are $2.3 million in Q2 2023, $3.3 million for Q1 2023, and $3.4 million during Q4 2022.